$ATRS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ANTARES PHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ANTARES PHARMA, INC.. Get notifications about new insider transactions in ANTARES PHARMA, INC. for free.
Page: < prev 1 2 3 4 5 6 7 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 58,251 | 144,445 | 7,716,880 | 7.8 M to 7.7 M (-0.75 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 74,137 | 183,838 | 9,821,484 | 9.9 M to 9.8 M (-0.75 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 28,574 | 70,469 | 3,854,380 | 3.9 M to 3.9 M (-0.74 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 24,612 | 61,030 | 3,882,954 | 3.9 M to 3.9 M (-0.63 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.18 | 198,789 | 433,360 | 198,789 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President & CEO | Option Exercise | A | 2.18 | 498,310 | 1,086,316 | 498,310 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President & CEO | Grant | A | 0.00 | 245,532 | 0 | 445,254 | 199.7 K to 445.3 K (+122.94 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Option Exercise | A | 2.18 | 193,241 | 421,265 | 193,241 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Grant | A | 0.00 | 95,216 | 0 | 135,216 | 40 K to 135.2 K (+238.04 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | A | 2.18 | 288,786 | 629,553 | 288,786 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 142,294 | 0 | 457,164 | 314.9 K to 457.2 K (+45.19 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 2.18 | 3,389 | 7,388 | 314,870 | 318.3 K to 314.9 K (-1.06 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 2.10 | 3,526 | 7,405 | 318,259 | 321.8 K to 318.3 K (-1.10 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Option Exercise | A | 2.18 | 142,550 | 310,759 | 142,550 | |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Grant | A | 0.00 | 70,239 | 0 | 92,042 | 21.8 K to 92 K (+322.15 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Payment of Exercise | F | 2.18 | 2,469 | 5,382 | 21,803 | 24.3 K to 21.8 K (-10.17 %) |
| Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
| Mar 24 2015 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 2.68 | 19,100 | 51,188 | 168,885 | 188 K to 168.9 K (-10.16 %) |
| Mar 24 2015 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 2.69 | 4,400 | 11,836 | 187,985 | 192.4 K to 188 K (-2.29 %) |
| Mar 12 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | A | 2.62 | 95,500 | 250,210 | 95,500 | |
| Mar 12 2015 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Option Exercise | A | 2.62 | 10,000 | 26,200 | 10,000 | |
| Mar 12 2015 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President & CEO | Option Exercise | A | 2.62 | 92,500 | 242,350 | 92,500 | |
| Mar 12 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Option Exercise | A | 2.62 | 47,000 | 123,140 | 47,000 | |
| Feb 12 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 2.36 | 4,779 | 11,278 | 326,619 | 331.4 K to 326.6 K (-1.44 %) |
| Feb 12 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 12,519 | 0 | 331,398 | 318.9 K to 331.4 K (+3.93 %) |
| Jan 14 2015 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.40 | 20,000 | 28,000 | 0 | |
| Jan 14 2015 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.40 | 20,000 | 28,000 | 9,006,413 | 9 M to 9 M (+0.22 %) |
| Dec 15 2014 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Buy | P | 2.50 | 40,000 | 99,800 | 40,000 | 0 to 40 K |
| Nov 24 2014 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Option Exercise | A | 2.29 | 150,000 | 343,500 | 150,000 | |
| Sep 12 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President and CEO | Buy | P | 2.20 | 9,000 | 19,800 | 382,446 | 373.4 K to 382.4 K (+2.41 %) |
| Aug 14 2014 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Buy | P | 1.96 | 5,000 | 9,795 | 28,172 | 23.2 K to 28.2 K (+21.58 %) |
| Aug 13 2014 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | P | 1.98 | 5,000 | 9,900 | 130,213 | 125.2 K to 130.2 K (+3.99 %) |
| Aug 13 2014 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Buy | P | 2.00 | 5,000 | 10,000 | 252,776 | 247.8 K to 252.8 K (+2.02 %) |
| Aug 12 2014 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | P | 1.98 | 10,000 | 19,800 | 192,385 | 182.4 K to 192.4 K (+5.48 %) |
| Aug 12 2014 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | P | 2.00 | 25,000 | 49,900 | 52,778 | 27.8 K to 52.8 K (+90.00 %) |
| Jun 25 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President and CEO | Option Exercise | A | 3.01 | 159,498 | 480,089 | 691,930 | |
| Jun 25 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President and CEO | Option Exercise | A | 3.01 | 340,502 | 1,024,911 | 532,432 | |
| Jun 25 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President and CEO | Grant | A | 0.00 | 91,362 | 0 | 373,446 | 282.1 K to 373.4 K (+32.39 %) |
| Jun 25 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President and CEO | Grant | A | 0.00 | 182,724 | 0 | 282,084 | 99.4 K to 282.1 K (+183.90 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | A | 3.09 | 56,300 | 173,967 | 1,169,982 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 32,362 | 0 | 441,005 | 408.6 K to 441 K (+7.92 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 64,725 | 0 | 408,643 | 343.9 K to 408.6 K (+18.82 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Option Exercise | A | 3.09 | 100,000 | 309,000 | 100,000 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Grant | A | 0.00 | 24,272 | 0 | 72,816 | 48.5 K to 72.8 K (+50.00 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Grant | A | 0.00 | 48,544 | 0 | 48,544 | 0 to 48.5 K |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 311,930 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | A | 3.09 | 154,825 | 478,409 | 1,572,308 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 88,997 | 0 | 937,725 | 848.7 K to 937.7 K (+10.49 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 177,994 | 0 | 848,728 | 670.7 K to 848.7 K (+26.54 %) |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 261,930 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 268,881 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 191,930 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 3.09 | 123,860 | 382,727 | 748,707 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 81,930 | |
| Jun 02 2014 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 3.09 | 61,930 | 191,364 | 81,930 | |
| Feb 24 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Payment of Exercise | F | 4.85 | 3,309 | 16,049 | 670,734 | 674 K to 670.7 K (-0.49 %) |
| Feb 24 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 10,309 | 0 | 674,043 | 663.7 K to 674 K (+1.55 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 4.45 | 7,752 | 34,496 | 343,918 | 351.7 K to 343.9 K (-2.20 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Sell | D | 0.00 | 25,000 | 0 | 351,670 | 376.7 K to 351.7 K (-6.64 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 4.45 | 3,484 | 15,504 | 376,670 | 380.2 K to 376.7 K (-0.92 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 11,236 | 0 | 380,154 | 368.9 K to 380.2 K (+3.05 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Payment of Exercise | F | 4.45 | 11,000 | 48,950 | 663,734 | 674.7 K to 663.7 K (-1.63 %) |
| Feb 13 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | D | 0.00 | 34,000 | 0 | 674,734 | 708.7 K to 674.7 K (-4.80 %) |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 22,900 | 11,450 | 1,417,483 | |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 5.10 | 22,900 | 116,758 | 708,734 | 731.6 K to 708.7 K (-3.13 %) |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 22,900 | 11,450 | 731,634 | 708.7 K to 731.6 K (+3.23 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.40 | 1,250 | 1,750 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 0.70 | 1,250 | 875 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 0.90 | 2,000 | 1,800 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 0.95 | 500 | 475 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.01 | 2,000 | 2,020 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.32 | 500 | 660 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.40 | 2,000 | 2,800 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.10 | 2,000 | 2,200 | 0 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.40 | 1,250 | 1,750 | 8,986,413 | 9 M to 9 M (+0.01 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 0.70 | 1,250 | 875 | 8,985,163 | 9 M to 9 M (+0.01 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 0.90 | 2,000 | 1,800 | 8,983,913 | 9 M to 9 M (+0.02 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 0.95 | 500 | 475 | 8,981,913 | 9 M to 9 M (+0.01 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.01 | 2,000 | 2,020 | 8,981,413 | 9 M to 9 M (+0.02 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.32 | 500 | 660 | 8,979,413 | 9 M to 9 M (+0.01 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.40 | 2,000 | 2,800 | 8,978,913 | 9 M to 9 M (+0.02 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.10 | 2,000 | 2,200 | 8,976,913 | 9 M to 9 M (+0.02 %) |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.50 | 11,400 | 5,700 | 624,847 | |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 5.05 | 11,400 | 57,571 | 126,829 | 138.2 K to 126.8 K (-8.25 %) |
| Jan 17 2014 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.50 | 11,400 | 5,700 | 138,229 | 126.8 K to 138.2 K (+8.99 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | M | 0.47 | 10,000 | 4,700 | 1,113,682 | |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Sell | S | 5.00 | 10,000 | 50,000 | 368,918 | 378.9 K to 368.9 K (-2.64 %) |
| Jan 14 2014 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Buy | M | 0.47 | 10,000 | 4,700 | 378,918 | 368.9 K to 378.9 K (+2.71 %) |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 18,100 | 9,050 | 1,440,383 | |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 46,000 | 23,000 | 1,458,483 | |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.00 | 18,100 | 72,447 | 708,734 | 726.8 K to 708.7 K (-2.49 %) |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 18,100 | 9,050 | 726,834 | 708.7 K to 726.8 K (+2.55 %) |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.00 | 46,000 | 184,198 | 708,734 | 754.7 K to 708.7 K (-6.09 %) |
| Dec 10 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 46,000 | 23,000 | 754,734 | 708.7 K to 754.7 K (+6.49 %) |
| Oct 16 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | M | 0.47 | 22,000 | 10,340 | 1,123,682 | |
| Oct 16 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Sell | S | 5.05 | 22,000 | 111,199 | 368,918 | 390.9 K to 368.9 K (-5.63 %) |
| Oct 16 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Buy | M | 0.47 | 22,000 | 10,340 | 390,918 | 368.9 K to 390.9 K (+5.96 %) |
| Oct 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 35,000 | 17,500 | 1,504,483 | |
| Oct 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.19 | 35,000 | 146,510 | 708,734 | 743.7 K to 708.7 K (-4.71 %) |
| Oct 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 35,000 | 17,500 | 743,734 | 708.7 K to 743.7 K (+4.94 %) |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.06 | 20,500 | 21,730 | 0 | |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.13 | 500 | 565 | 0 | |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.30 | 7,000 | 9,100 | 0 | |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.06 | 20,500 | 21,730 | 8,974,913 | 9 M to 9 M (+0.23 %) |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.13 | 500 | 565 | 8,954,413 | 9 M to 9 M (+0.01 %) |
| Oct 09 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.30 | 7,000 | 9,100 | 8,953,913 | 8.9 M to 9 M (+0.08 %) |
| Sep 05 2013 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Sell | S | 4.42 | 25,000 | 110,570 | 245,976 | 271 K to 246 K (-9.23 %) |
| Sep 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 35,000 | 17,500 | 1,539,483 | |
| Sep 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.41 | 35,000 | 154,378 | 708,734 | 743.7 K to 708.7 K (-4.71 %) |
| Sep 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 35,000 | 17,500 | 743,734 | 708.7 K to 743.7 K (+4.94 %) |
| Aug 12 2013 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 4.54 | 20,000 | 90,800 | 20,000 | |
| Aug 12 2013 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Grant | A | 0.00 | 18,172 | 0 | 23,172 | 5 K to 23.2 K (+363.44 %) |
| Aug 05 2013 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Sell | S | 4.41 | 25,000 | 110,355 | 270,976 | 296 K to 271 K (-8.45 %) |
| Aug 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 35,000 | 17,500 | 1,574,483 | |
| Aug 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.42 | 35,000 | 154,592 | 708,734 | 743.7 K to 708.7 K (-4.71 %) |
| Aug 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 35,000 | 17,500 | 743,734 | 708.7 K to 743.7 K (+4.94 %) |
| Jul 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 35,000 | 17,500 | 1,609,483 | |
| Jul 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.14 | 35,000 | 144,974 | 708,734 | 743.7 K to 708.7 K (-4.71 %) |
| Jul 03 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 35,000 | 17,500 | 743,734 | 708.7 K to 743.7 K (+4.94 %) |
| Jul 03 2013 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Sell | S | 4.15 | 25,000 | 103,685 | 295,976 | 321 K to 296 K (-7.79 %) |
| Jun 27 2013 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | Director | Sell | S | 4.19 | 23,500 | 98,465 | 99,360 | 122.9 K to 99.4 K (-19.13 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Option Exercise | M | 0.47 | 48,000 | 22,560 | 647,195 | |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Sell | S | 4.01 | 48,000 | 192,547 | 265,028 | 313 K to 265 K (-15.33 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Buy | M | 0.47 | 48,000 | 22,560 | 313,028 | 265 K to 313 K (+18.11 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | M | 0.50 | 125,000 | 62,500 | 1,644,483 | |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Sell | S | 4.01 | 125,000 | 501,138 | 708,734 | 833.7 K to 708.7 K (-14.99 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Buy | M | 0.50 | 125,000 | 62,500 | 833,734 | 708.7 K to 833.7 K (+17.64 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | M | 0.47 | 28,600 | 13,442 | 1,145,682 | |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | M | 0.47 | 86,400 | 40,608 | 1,174,282 | |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Sell | S | 4.03 | 28,600 | 115,126 | 368,918 | 397.5 K to 368.9 K (-7.19 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Buy | M | 0.47 | 28,600 | 13,442 | 397,518 | 368.9 K to 397.5 K (+7.75 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Sell | S | 4.01 | 86,400 | 346,792 | 368,918 | 455.3 K to 368.9 K (-18.98 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Buy | M | 0.47 | 86,400 | 40,608 | 455,318 | 368.9 K to 455.3 K (+23.42 %) |
| Jun 05 2013 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Sell | S | 4.01 | 25,000 | 100,355 | 320,976 | 346 K to 321 K (-7.23 %) |
| Jun 03 2013 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.08 | 13,000 | 53,001 | 125,213 | 138.2 K to 125.2 K (-9.41 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 3.96 | 20,000 | 79,200 | 20,000 | |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Grant | A | 0.00 | 27,778 | 0 | 27,778 | 0 to 27.8 K |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Option Exercise | A | 3.96 | 52,083 | 206,249 | 695,195 | |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Grant | A | 0.00 | 29,461 | 0 | 265,028 | 235.6 K to 265 K (+12.51 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | DAVE KAUSHIK J | Executive Vice Pres ... | Grant | A | 0.00 | 29,461 | 0 | 235,567 | 206.1 K to 235.6 K (+14.29 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | A | 3.96 | 59,524 | 235,715 | 1,260,682 | |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 33,670 | 0 | 368,918 | 335.2 K to 368.9 K (+10.04 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 33,670 | 0 | 335,248 | 301.6 K to 335.2 K (+11.16 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Option Exercise | A | 3.96 | 163,690 | 648,212 | 1,769,483 | |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 92,593 | 0 | 708,734 | 616.1 K to 708.7 K (+15.03 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 92,593 | 0 | 616,141 | 523.5 K to 616.1 K (+17.69 %) |
| May 24 2013 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Grant | A | 0.00 | 27,778 | 0 | 8,946,913 | 8.9 M to 8.9 M (+0.31 %) |